



**Australian Government**

**Department of Health**  
Therapeutic Goods Administration

**Therapeutic Goods Act 1989**  
**Approval under section 42DF for use of restricted representations by**  
**iNova Pharmaceuticals (Australia) Pty Ltd**

I, Elizabeth Butt, as a delegate of the Secretary to the Department of Health, on receipt of an application from iNova Pharmaceuticals (Australia) Pty Ltd, have approved under section 42DF of the *Therapeutic Goods Act 1989* (the **Act**) the restricted representations described in paragraph **(A)** below for use in consumer advertising of the products identified in paragraph **(B)**:

- (A)** Representations to the effect that the Medicines *can be used for the temporary relief of pain associated with arthritis, osteoarthritis, fibrositis, neuralgia, and rheumatic pain* (where referenced individually or collectively)
- (B)** NYAL PARACETAMOL, paracetamol 500mg mg tablet blister pack (AUST R 350070)  
NYAL PARACETAMOL, paracetamol 500mg capsule blister pack (AUST R 350254),  
(the **Medicines**).

Dated this 23<sup>rd</sup> day of July 2021

*Signed electronically*

Elizabeth Butt  
Delegate of the Secretary to the Department of Health  
Advertising and Compliance Education and Policy Section  
Regulatory Compliance Branch